April - June 2019, Volume 15, Issue 2

Chabre O, Cristante J

Treatment of Cushing’s Syndrome : What Place for Medical Treatment?

Acta Endo (Buc) 2019, 15 (2): 237-243
doi: 10.4183/aeb.2019.237

Surgery plays a major role as a first-line treatment of the different etiologies of Cushing’s syndrome (CS) and bilateral adrenalectomy (BA) is extremely effective as a second line, so that there seems to be little room for medical treatment (MT). However, during the past years several drugs acting either on ACTH secretion or cortisol synthesis have been developed, so that MT of CS might be reassessed. After briefly analyzing the efficiency and tolerance of surgical and medical treatments of CS we try to distinguish consensual and controversial indications for MT. We believe the former include “pre-operative treatment” in rare patients in whom the severity of CS is likely to increase the risks of surgery; “inoperability” for rare patients who cannot be operated even when CS is controlled and “surgical failure or recurrence”, mainly in patients Cushing’s disease (CD) not in remission after TSS. Controversial indications include “unavailability of an expert surgeon”, which we believe does not make sense when the cost of MT is taken into consideration. Finally in patients with the “surgical failure or recurrence” indication the balance between efficacy and side effects of MT should be balanced with the efficacy and side effects of BA.

Keywords: Cushing’s, pituitary surgery.

Correspondence: Olivier Chabre PhD, CHU Grenoble Alpes - Endocrinology, CS 10217, Grenoble, 38043, France, E-mail: olivierchabre@chu-grenoble.fr